Roll Over StudY for Patients Who Have Completed a Previous Oncology Study with Durvalumab - ROSY-D

Study identifier:D4191C00137

ClinicalTrials.gov identifier:NCT05303532

EudraCT identifier:2021-003031-29

CTIS identifier:2023-507337-22-00

Recruiting

Official Title

ROSY-D: Roll Over StudY for Patients Who Have Completed a Previous Oncology Study with Durvalumab and Are Judged by the Investigator to Clinically Benefit From Continued Treatment

Medical condition

cancer

Phase

Phase 3

Healthy volunteers

No

Study drug

Durvalumab

Sex

All

Estimated Enrollment

61

Study type

Interventional

Age

18 Years - 99 Years

Date

Study Start Date: 19 Apr 2022
Estimated Primary Completion Date: 07 Jan 2026
Estimated Study Completion Date: 07 Jan 2026

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: Sequential Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Nov 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria